These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 26186909)
21. C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin. Gao Z; Xu X; McClane B; Zeng Q; Litkouhi B; Welch WR; Berkowitz RS; Mok SC; Garner EI Clin Cancer Res; 2011 Mar; 17(5):1065-74. PubMed ID: 21123456 [TBL] [Abstract][Full Text] [Related]
22. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240 [TBL] [Abstract][Full Text] [Related]
23. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer. Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272 [TBL] [Abstract][Full Text] [Related]
24. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309 [TBL] [Abstract][Full Text] [Related]
25. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397 [TBL] [Abstract][Full Text] [Related]
26. Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants. Heinze K; Kritsch D; Mosig AS; Dürst M; Häfner N; Runnebaum IB Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342962 [TBL] [Abstract][Full Text] [Related]
27. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177 [TBL] [Abstract][Full Text] [Related]
28. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells. Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893 [TBL] [Abstract][Full Text] [Related]
29. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Guo P; Xiong X; Zhang S; Peng D Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936 [TBL] [Abstract][Full Text] [Related]
30. The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer. Nusrat O; Belotte J; Fletcher NM; Memaj I; Saed MG; Diamond MP; Saed GM Reprod Sci; 2016 Nov; 23(11):1484-1492. PubMed ID: 27122375 [TBL] [Abstract][Full Text] [Related]
31. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells. Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577 [TBL] [Abstract][Full Text] [Related]
32. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer. Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793 [TBL] [Abstract][Full Text] [Related]
33. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids. Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799 [TBL] [Abstract][Full Text] [Related]
34. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231 [TBL] [Abstract][Full Text] [Related]
37. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation. Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819 [TBL] [Abstract][Full Text] [Related]
38. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway. Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551 [TBL] [Abstract][Full Text] [Related]
39. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Wu YH; Chang TH; Huang YF; Chen CC; Chou CY Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191 [TBL] [Abstract][Full Text] [Related]
40. Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake. Lv X; Song J; Xue K; Li Z; Li M; Zahid D; Cao H; Wang L; Song W; Ma T; Gu J; Li W Mol Carcinog; 2019 May; 58(5):794-807. PubMed ID: 30614075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]